Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verdiperstat (Primary)
Indications Multiple system atrophy
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms M-STAR
Sponsors Biohaven Pharmaceuticals

Most Recent Events

18 Sep 2022 Results assessing the safety and efficacy of Verdiperstat presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
26 Jul 2022 Status changed from active, no longer recruiting to completed.
27 Sep 2021 According to a Biohaven Pharmaceutical media release, additional analyses from this trial are still pending, and full study results will be presented at an upcoming scientific meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com